Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.


Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
07 2022
Historique:
received: 24 06 2021
revised: 17 01 2022
accepted: 23 01 2022
pubmed: 9 2 2022
medline: 22 6 2022
entrez: 8 2 2022
Statut: ppublish

Résumé

Acetaminophen (APAP) overdose remains a frequent cause of acute liver failure, which is generally accompanied by increased levels of serum bile acids (BAs). However, the pathophysiological role of BAs remains elusive. Herein, we investigated the role of BAs in APAP-induced hepatotoxicity. We performed intravital imaging to investigate BA transport in mice, quantified endogenous BA concentrations in the serum of mice and patients with APAP overdose, analyzed liver tissue and bile by mass spectrometry and MALDI-mass spectrometry imaging, assessed the integrity of the blood-bile barrier and the role of oxidative stress by immunostaining of tight junction proteins and intravital imaging of fluorescent markers, identified the intracellular cytotoxic concentrations of BAs, and performed interventions to block BA uptake from blood into hepatocytes. Prior to the onset of cell death, APAP overdose causes massive oxidative stress in the pericentral lobular zone, which coincided with a breach of the blood-bile barrier. Consequently, BAs leak from the bile canaliculi into the sinusoidal blood, which is then followed by their uptake into hepatocytes via the basolateral membrane, their secretion into canaliculi and repeated cycling. This, what we termed 'futile cycling' of BAs, led to increased intracellular BA concentrations that were high enough to cause hepatocyte death. Importantly, however, the interruption of BA re-uptake by pharmacological NTCP blockage using Myrcludex B and Oatp knockout strongly reduced APAP-induced hepatotoxicity. APAP overdose induces a breach of the blood-bile barrier which leads to futile BA cycling that causes hepatocyte death. Prevention of BA cycling may represent a therapeutic option after APAP intoxication. Only one drug, N-acetylcysteine, is approved for the treatment of acetaminophen overdose and it is only effective when given within ∼8 hours after ingestion. We identified a mechanism by which acetaminophen overdose causes an increase in bile acid concentrations (to above toxic thresholds) in hepatocytes. Blocking this mechanism prevented acetaminophen-induced hepatotoxicity in mice and evidence from patients suggests that this therapy may be effective for longer periods after ingestion compared to N-acetylcysteine.

Sections du résumé

BACKGROUND & AIMS
Acetaminophen (APAP) overdose remains a frequent cause of acute liver failure, which is generally accompanied by increased levels of serum bile acids (BAs). However, the pathophysiological role of BAs remains elusive. Herein, we investigated the role of BAs in APAP-induced hepatotoxicity.
METHODS
We performed intravital imaging to investigate BA transport in mice, quantified endogenous BA concentrations in the serum of mice and patients with APAP overdose, analyzed liver tissue and bile by mass spectrometry and MALDI-mass spectrometry imaging, assessed the integrity of the blood-bile barrier and the role of oxidative stress by immunostaining of tight junction proteins and intravital imaging of fluorescent markers, identified the intracellular cytotoxic concentrations of BAs, and performed interventions to block BA uptake from blood into hepatocytes.
RESULTS
Prior to the onset of cell death, APAP overdose causes massive oxidative stress in the pericentral lobular zone, which coincided with a breach of the blood-bile barrier. Consequently, BAs leak from the bile canaliculi into the sinusoidal blood, which is then followed by their uptake into hepatocytes via the basolateral membrane, their secretion into canaliculi and repeated cycling. This, what we termed 'futile cycling' of BAs, led to increased intracellular BA concentrations that were high enough to cause hepatocyte death. Importantly, however, the interruption of BA re-uptake by pharmacological NTCP blockage using Myrcludex B and Oatp knockout strongly reduced APAP-induced hepatotoxicity.
CONCLUSIONS
APAP overdose induces a breach of the blood-bile barrier which leads to futile BA cycling that causes hepatocyte death. Prevention of BA cycling may represent a therapeutic option after APAP intoxication.
LAY SUMMARY
Only one drug, N-acetylcysteine, is approved for the treatment of acetaminophen overdose and it is only effective when given within ∼8 hours after ingestion. We identified a mechanism by which acetaminophen overdose causes an increase in bile acid concentrations (to above toxic thresholds) in hepatocytes. Blocking this mechanism prevented acetaminophen-induced hepatotoxicity in mice and evidence from patients suggests that this therapy may be effective for longer periods after ingestion compared to N-acetylcysteine.

Identifiants

pubmed: 35131407
pii: S0168-8278(22)00062-9
doi: 10.1016/j.jhep.2022.01.020
pmc: PMC9209783
pii:
doi:

Substances chimiques

Bile Acids and Salts 0
Acetaminophen 362O9ITL9D
Acetylcysteine WYQ7N0BPYC

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

71-83

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest S.U. is holder and inventor on patents protecting Myrcludex B (Hepcludex/bulevirtide). All other authors declare that they have no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Références

Cell Physiol Biochem. 2013;32(2):431-47
pubmed: 23988609
Toxicol Appl Pharmacol. 2013 Dec 15;273(3):524-31
pubmed: 24096036
Expert Opin Drug Metab Toxicol. 2020 Nov;16(11):1039-1050
pubmed: 32862728
Liver Int. 2012 Jan;32(1):58-69
pubmed: 22098667
Hepatology. 2013 Apr;57(4):1394-406
pubmed: 23299969
Toxicol Sci. 2014 Dec;142(2):436-44
pubmed: 25239633
PLoS One. 2011;6(7):e22094
pubmed: 21760958
Semin Liver Dis. 2019 May;39(2):221-234
pubmed: 30849782
Hepatology. 2012 Jul;56(1):209-18
pubmed: 22290718
J Hepatol. 2017 Apr;66(4):836-848
pubmed: 27913221
J Hepatol. 2021 Jul;75(1):190-201
pubmed: 33617926
Ann Hepatol. 2008 Jan-Mar;7(1):16-33
pubmed: 18376363
Compr Physiol. 2013 Apr;3(2):977-1010
pubmed: 23720337
Sci Rep. 2017 Jan 30;7:37541
pubmed: 28134251
Hepatology. 2019 Feb;69(2):666-683
pubmed: 30102412
Arch Toxicol. 2019 Dec;93(12):3491-3502
pubmed: 31641808
Hepatology. 2013 Oct;58(4):1451-60
pubmed: 23686672
Hepatology. 2018 Sep;68(3):1057-1069
pubmed: 29572910
Hepatology. 2017 Nov;66(5):1631-1643
pubmed: 28498614

Auteurs

Ahmed Ghallab (A)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany; Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, South Valley University, 83523, Qena, Egypt. Electronic address: ghallab@ifado.de.

Reham Hassan (R)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany; Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, South Valley University, 83523, Qena, Egypt.

Ute Hofmann (U)

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen, Auerbachstr. 112, 70376 Stuttgart, Germany.

Adrian Friebel (A)

Institute of Computer Science & Saxonian Incubator for Clinical Research (SIKT), University of Leipzig, Haertelstraße 16-18, 04107, Leipzig, Germany.

Zaynab Hobloss (Z)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany.

Lisa Brackhagen (L)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany.

Brigitte Begher-Tibbe (B)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany.

Maiju Myllys (M)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany.

Joerg Reinders (J)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany.

Nina Overbeck (N)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany.

Selahaddin Sezgin (S)

Faculty of Chemistry and Chemical Biology, TU Dortmund, Dortmund, Germany.

Sebastian Zühlke (S)

Center for Mass Spectrometry (CMS), Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany.

Abdel-Latif Seddek (AL)

Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, South Valley University, 83523, Qena, Egypt.

Walaa Murad (W)

Histology Department, Faculty of Medicine, South Valley University, 83523 Qena, Egypt.

Tim Brecklinghaus (T)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany.

Franziska Kappenberg (F)

Department of Statistics, TU Dortmund University, 44227, Dortmund, Germany.

Jörg Rahnenführer (J)

Department of Statistics, TU Dortmund University, 44227, Dortmund, Germany.

Daniela González (D)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany.

Christopher Goldring (C)

Department of Pharmacology and Therapeutics, MRC Centre of Drug Safety Science, University of Liverpool, The Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK.

Ian M Copple (IM)

Department of Pharmacology and Therapeutics, MRC Centre of Drug Safety Science, University of Liverpool, The Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK.

Rosemarie Marchan (R)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany.

Thomas Longerich (T)

Translational Gastrointestinal Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Mihael Vucur (M)

Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty at Heinrich-Heine-University, Dusseldorf, Germany.

Tom Luedde (T)

Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty at Heinrich-Heine-University, Dusseldorf, Germany.

Stephan Urban (S)

Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany; German Center for Infection Research, Heidelberg University, Heidelberg, Germany.

Ali Canbay (A)

Department of Medicine, Ruhr University Bochum, University Hospital Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Thomas Schreiter (T)

Department of Medicine, Ruhr University Bochum, University Hospital Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Michael Trauner (M)

Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

Jephte Y Akakpo (JY)

Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.

Mojtaba Olyaee (M)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.

Steven C Curry (SC)

Division of Clinical Data Analytics and Decision Support, Division of Medical Toxicology and Precision Medicine, Department of Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.

Jan-Peter Sowa (JP)

Department of Medicine, Ruhr University Bochum, University Hospital Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.

Hartmut Jaeschke (H)

Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.

Stefan Hoehme (S)

Institute of Computer Science & Saxonian Incubator for Clinical Research (SIKT), University of Leipzig, Haertelstraße 16-18, 04107, Leipzig, Germany.

Jan G Hengstler (JG)

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystr. 67, 44139, Dortmund, Germany. Electronic address: hengstler@ifado.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH